论文部分内容阅读
目的：了解硒酸酯多糖对肿瘤患者体内ＭＤＡ及ＣｕＺｎ－ＳＯＤ活性的影响。方法：对６０例肿瘤病人随机分成３组：不服硒组，服硒４００μｇ／ｄ组及服８００μｇ／ｄ组并与１５名正常人对照比较。结果：癌症患者血清ＭＤＡ明显高于正常人（Ｐ＜０．０１），血清Ｓｅ及ＣｕＺｎ－ＳＯＤ活性明显低于正常人（Ｐ＜０．０１，Ｐ＜０．０５）；服硒酸酯多糖者化疗后血清Ｓｅ较不服者明显升高（Ｐ＜０．０５），ＣｕＺｎ－ＳＯＤ也明显升高（Ｐ＜０．０１），ＭＤＡ含量显著下降（Ｐ＜０．０５）；服４００μｇ／ｄ组与服８００μｇ／ｄ组之间上述各指标均无明显差异。结论：肿瘤病人摄入适量（４００μｇ／ｄ）硒酸酯多糖可能增加体内ＣｕＺｎ－ＳＯＤ活性，减轻了化疗药物对正常细胞的过氧化损伤。
Objective: To understand the effect of selenate polysaccharide on the activity of MDA and CuZn-SOD in tumor patients. METHODS: Sixty tumor patients were randomly divided into three groups: untreated selenium group, selenium 400 μg/d group and 800 μg/d group and compared with 15 normal controls. Results: The serum MDA in cancer patients was significantly higher than normal (P<0.01). The activity of Se and CuZn-SOD in serum were significantly lower than normal (P<0.01, P<0.05); After chemotherapy, serum Se levels were significantly higher (P<0.05), CuZn-SOD was also significantly increased (P<0.01), and MDA levels were significantly decreased (P<0.05); Serving 400 μg/d There was no significant difference in the above indicators between the 800 μg/d group and the group. Conclusion: The intake of appropriate amount (400 μg/d) of selenate polysaccharide in tumor patients may increase the activity of CuZn-SOD in vivo, and reduce the peroxidative damage of chemotherapy drugs to normal cells.